This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chiu, A. C. Articles by Sherman, S. I. Search for Related Content PubMed PubMed Citation Articles by Chiu, A. C. Articles by Sherman, S. I.

Prognosis and Treatment of Brain Metastases in Thyroid Carcinoma

Sections of Endocrine Neoplasia and Hormonal Disorders (A.C.C., S.I.S.) and Clinical Nuclear Medicine (E.S.D.), University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Address all correspondence and requests for reprints to: Steven I. Sherman, M.D., University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 15, Houston, Texas 77030.

We analyzed 47 cases of brain metastases from thyroid cancer seen at 1 institution over 5 decades. Brain metastases were a primary clinical feature at initial presentation in 15% of the cases, were identified during the subsequent course of the disease in 68%, and were only discovered at autopsy in 23%. The primary thyroid tumor was differentiated cancer in 68%, anaplastic cancer in 23%, and medullary cancer in 9%. Patients were typically older, with frequent evidence of aggressive disease and distant metastases at initial cancer diagnosis. Once brain metastases were diagnosed, disease-specific mortality was 78%, with a median product-limit survival of 4.7 months (67% and 12.4 months, respectively, for those with differentiated cancer). Resection of one or more foci of brain metastases significantly improved survival. The median disease-specific survival from diagnosis of brain metastases was 16.7 months for patients who underwent local excision of one or more brain metastases, compared with 3.4 months for those who did not (P < 0.05), independent of the presence of multifocal brain lesions. Recombinant human TSH safely stimulated radioiodine uptake for treatment of brain metastases in 1 patient. However, no evidence of survival benefit was found from radioiodine therapy, external beam radiotherapy, or chemotherapy. In summary, brain metastases from thyroid carcinoma are an extremely poor prognostic sign. Although selection bias and other unidentified factors inherent to retrospective analysis limit this conclusion, surgical resection of brain metastases may be associated with prolonged survival in differentiated carcinoma.

This article has been cited by other articles:

				M. Luster, F. Lippi, B. Jarzab, P. Perros, M. Lassmann, C. Reiners, and F. Pacini rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review Endocr. Relat. Cancer, March 1, 2005; 12(1): 49 - 64. [Abstract] [Full Text] [PDF]

				D. Barbaro, G. Boni, G. Meucci, U. Simi, P. Lapi, P. Orsini, C. Pasquini, F. Piazza, M. Caciagli, and G. Mariani Radioiodine Treatment with 30 mCi after Recombinant Human Thyrotropin Stimulation in Thyroid Cancer: Effectiveness for Postsurgical Remnants Ablation and Possible Role of Iodine Content in L-Thyroxine in the Outcome of Ablation J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4110 - 4115. [Abstract] [Full Text] [PDF]

				R. J. Robbins and A. K. Robbins Recombinant Human Thyrotropin and Thyroid Cancer Management J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1933 - 1938. [Full Text] [PDF]

				M. Braga, M. D. Ringel, and D. S. Cooper Sudden Enlargement of Local Recurrent Thyroid Tumor after Recombinant Human TSH Administration J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5148 - 5151. [Abstract] [Full Text] [PDF]

				E. L. Mazzaferri and R. T. Kloos Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1447 - 1463. [Full Text]

				M. Luster, M. Lassmann, H. Haenscheid, U. Michalowski, C. Incerti, and C. Reiners Use of Recombinant Human Thyrotropin before Radioiodine Therapy in Patients with Advanced Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3640 - 3645. [Abstract] [Full Text]

				P. Rotman-Pikielny, J. C. Reynolds, W. C. Barker, P. M. Yen, M. C. Skarulis, and N. J. Sarlis Recombinant Human Thyrotropin for the Diagnosis and Treatment of a Highly Functional Metastatic Struma Ovarii J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 237 - 244. [Abstract] [Full Text]

				G. E. Vargas, H. Uy, C. Bazan, T. A. Guise, and J. M. Bruder Hemiplegia after Thyrotropin Alfa in a Hypothyroid Patient with Thyroid Carcinoma Metastatic to the Brain J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 3867 - 3871. [Full Text]

				Y. Kitamura, K. Shimizu, M. Nagahama, K. Sugino, O. Ozaki, T. Mimura, K. Ito, K. Ito, and S. Tanaka Immediate Causes of Death in Thyroid Carcinoma: Clinicopathological Analysis of 161 Fatal Cases J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 4043 - 4049. [Abstract] [Full Text]

				S. I. Sherman and J. Gopal Thyroglobulin Positive, RAI Negative Thyroid Cancers: The Role of Conservative Management J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4199 - 4200. [Full Text]